ClinicalTrials.gg
TerminatedNCT05632354Updated Mar 19, 2026Results posted

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

A Phase 2/3 interventional study of Osivelotor in Sickle Cell Disease, sponsored by Pfizer. Terminated at 9 sites in 2 countries. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.

Enrollment
15th of 27
47 · median 52
Started
2023
with 3 others
Phase 2/3
2 of 32
1 open now
Registered
29th of 32
by date

Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 15th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 in phase 2/3, and was the 29th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Anemia, Sickle Cell by Pfizer, or all of them as a file.
02

Study summary

An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease

Read the detailed description

An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 6 months or older with SCD who participated and received study drug or placebo in a previous osivelotor clinical study and completed the end of treatment visit.

    Note: Participants who discontinued study drug in the originating study due to an TEAE, but who remained on study, may be eligible for treatment in this study provided the TEAE does not pose a risk for treatment with osivelotor.

  2. Females of are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Females who become of childbearing potential during the study must be willing to have negative urine pregnancy tests to remain in the study.

  3. If sexually active, females of childbearing potential must consistently use highly effective methods of consistently throughout the study and for at least 120 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 84 days after the last dose of study drug. Male participants are eligible to participate if they agree to the following requirements during the study intervention period and for 84 days after the last dose of study intervention:

    • Refrain from donating sperm PLUS either
    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle OR
    • Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person
  4. Participant has provided written /assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirements.

Exclusion criteria

Exclusion Criteria:

  • Participant withdrew consent or was noncompliant from the originating osivelotor clinical study
  • Current or recent use of voxelotor. Recent use is defined as within 10 days prior to Day 1
  • Current or recent use of crizanlizumab. Recent use is defined as within 90 days prior to Day 1
  • Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude
  • Has received an drug (including investigational vaccines) within 5 times the elimination half-life (if known) or within 30 days (if the elimination half-life- is unknown) prior to study drug administration or is concurrently enrolled in any research judged not to be scientifically or medically compatible with this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Treatment

    Osivelotor

    Drug: Osivelotor

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. Serious adverse events (SAEs) were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. TEAEs are events between first dose of study drug and up to 56 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of any AE to treatment was based on investigator decision. AEs included both SAEs and all non-serious AEs.

    Time frame: From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)

  2. Change From Baseline in Hematocrit at Week 12

    Change from baseline in hematocrit at week 12 were reported in this outcome measure.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Hematocrit at Week 48

    Change from baseline in hematocrit at week 48 were reported in this outcome measure.

    Time frame: Baseline, Week 48

  4. Change From Baseline in Leukocytes at Week 12

    Change from baseline in leukocytes at week 12 were reported in this outcome measure.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Leukocytes Week 48

    Change from baseline in leukocytes at week 48 were reported in this outcome measure.

    Time frame: Baseline, Week 48

  6. Change From Baseline in Supine Blood Pressure (SBP) at Week 12

    Change from baseline in SBP at week 12 were reported in this outcome measure.

    Time frame: Baseline, Week 12

  7. Change From Baseline in SBP at Week 48

    Change from baseline in SBP at week 48 were reported in this outcome measure.

    Time frame: Baseline, Week 48

  8. Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12

    Change from baseline in DBP at week 12 were reported in this outcome measure.

    Time frame: Baseline, Week 12

  9. Change From Baseline in DBP at Week 48

    Change from baseline in DBP at week 48 were reported in this outcome measure.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Annualized Rate of Vaso-Occlusive Crisis (VOC)

    A VOC was defined as an acute episode of pain that had no medically determined cause other than a vaso-occlusive event, and resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), and required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC was reported in this outcome measure.

    Time frame: From the first dose of study drug up to last dose of study drug (approximately up to 680 days)

  2. Number of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs)

    SCD is an inherited disorder caused by a point mutation in the beta globin gene which leads to formation of sickle hemoglobin (HbS). SAEs were defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. Participants with delayed start are those with a gap in dosing greater than 42 consecutive days from completing the originating study (C5351005 Date of First Dose - C5351004 End of Treatment Date + 1 greater than 42).

    Time frame: From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)

  3. Change From Baseline in Hemoglobin at Weeks 12, 24, 36, 48, and 60

    Change from baseline in hemoglobin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

    Time frame: Baseline, Weeks 12, 24, 36, 48, and 60

  4. Change From Baseline in Reticulocytes at Weeks 12, 24, 36, 48, and 60

    Change from baseline in reticulocytes at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

    Time frame: Baseline, Weeks 12, 24, 36, 48, and 60

  5. Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 12, 24, 36, 48, and 60

    Change from baseline in LDH at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

    Time frame: Baseline, Weeks 12, 24, 36, 48, and 60

  6. Change From Baseline in Unconjugated Bilirubin at Weeks 12, 24, 36, 48, and 60

    Change from baseline in unconjugated bilirubin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

    Time frame: Baseline, Weeks 12, 24, 36, 48, and 60

07

Results

Posted Mar 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneParticipants Without Delayed Start: Osivelotor 100 Milligram (mg)Participants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Started1817156
Completed00000
Not completed1817156
Withdrew: Adverse event00010
Withdrew: Lost to follow-up10000
Withdrew: Pregnancy30000
Withdrew: Study terminated by sponsor1216146
Withdrew: Withdrawal by subject11000
Withdrew: Non-compliance with study treatment10000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. Serious adverse events (SAEs) were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. TEAEs are events between first dose of study drug and up to 56 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of any AE to treatment was based on investigator decision. AEs included both SAEs and all non-serious AEs.

Time frame:
From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
TEAE1413156
Treatment related TEAE40000
Treatment emergent SAEs54122
Treatment-Related Treatment-Emergent SAEs10000
Treatment Emergent Non-Serious AEs1413155
PrimaryChange From Baseline in Hematocrit at Week 12

Change from baseline in hematocrit at week 12 were reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · Percent
Change From Baseline in Hematocrit at Week 12
PercentParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Hematocrit at Week 12-0.3 ± 5.88-3.9 ± 7.53-1.9 ± NA7.0 ± 5.7410.0 ± 2.37
PrimaryChange From Baseline in Hematocrit at Week 48

Change from baseline in hematocrit at week 48 were reported in this outcome measure.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent
Change From Baseline in Hematocrit at Week 48
PercentParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Hematocrit at Week 48-2.4 ± 7.71-5.5 ± 8.61-9.9 ± NA4.5 ± 4.125.5 ± 5.00
PrimaryChange From Baseline in Leukocytes at Week 12

Change from baseline in leukocytes at week 12 were reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · 10^9 cells per liter (10^9 cells/L)
Change From Baseline in Leukocytes at Week 12
10^9 cells per liter (10^9 cells/L)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Leukocytes at Week 121.7 ± 2.680.8 ± 1.870.9 ± NA0.3 ± 1.92-1.8 ± 2.28
PrimaryChange From Baseline in Leukocytes Week 48

Change from baseline in leukocytes at week 48 were reported in this outcome measure.

Time frame:
Baseline, Week 48
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Leukocytes Week 48
10^9 cells/LParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Leukocytes Week 481.7 ± 3.352.8 ± 3.222.4 ± NA1.0 ± 1.82-0.4 ± 1.74
PrimaryChange From Baseline in Supine Blood Pressure (SBP) at Week 12

Change from baseline in SBP at week 12 were reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Supine Blood Pressure (SBP) at Week 12
Millimeters of mercury (mmHg)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Supine Blood Pressure (SBP) at Week 12-3.4 ± 7.83-2.5 ± 10.72-3.0 ± NA2.0 ± 4.422.0 ± 5.10
PrimaryChange From Baseline in SBP at Week 48

Change from baseline in SBP at week 48 were reported in this outcome measure.

Time frame:
Baseline, Week 48
Reported as:
Mean · mmHg
Change From Baseline in SBP at Week 48
mmHgParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in SBP at Week 48-2.5 ± 12.34-2.3 ± 11.480.0 ± NA-0.8 ± 11.50-0.4 ± 9.43
PrimaryChange From Baseline in Diastolic Blood Pressure (DBP) at Week 12

Change from baseline in DBP at week 12 were reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12
mmHgParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12-3.9 ± 7.91-0.8 ± 7.28-2.0 ± NA1.0 ± 5.96-1.7 ± 14.04
PrimaryChange From Baseline in DBP at Week 48

Change from baseline in DBP at week 48 were reported in this outcome measure.

Time frame:
Baseline, Week 48
Reported as:
Mean · mmHg
Change From Baseline in DBP at Week 48
mmHgParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change From Baseline in DBP at Week 48-4.4 ± 8.99-0.4 ± 7.621.0 ± NA4.3 ± 13.55-1.5 ± 16.77
SecondaryAnnualized Rate of Vaso-Occlusive Crisis (VOC)

A VOC was defined as an acute episode of pain that had no medically determined cause other than a vaso-occlusive event, and resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), and required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC was reported in this outcome measure.

Time frame:
From the first dose of study drug up to last dose of study drug (approximately up to 680 days)
Reported as:
Number · VOC events per year
Annualized Rate of Vaso-Occlusive Crisis (VOC)
VOC events per yearAll Participants: Osivelotor 100 mgAll Participants: Osivelotor 150 mgAll Participants: Osivelotor 100 mg + 150 mgAll Participants: Osivelotor 200 mg
Annualized Rate of Vaso-Occlusive Crisis (VOC)1.01 (0.50 to 2.04)1.11 (0.59 to 2.09)1.07 (0.67 to 1.70)NA (NA to NA)
SecondaryNumber of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs)

SCD is an inherited disorder caused by a point mutation in the beta globin gene which leads to formation of sickle hemoglobin (HbS). SAEs were defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. Participants with delayed start are those with a gap in dosing greater than 42 consecutive days from completing the originating study (C5351005 Date of First Dose - C5351004 End of Treatment Date + 1 greater than 42).

Time frame:
From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)
Reported as:
Count of participants · Participants
Number of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs)
ParticipantsParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Number of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs)02100
SecondaryChange From Baseline in Hemoglobin at Weeks 12, 24, 36, 48, and 60

Change from baseline in hemoglobin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

Time frame:
Baseline, Weeks 12, 24, 36, 48, and 60
Reported as:
Mean · Grams per deciliter (g/dL)
Change From Baseline in Hemoglobin at Weeks 12, 24, 36, 48, and 60
Grams per deciliter (g/dL)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change at week 120.2 ± 1.68-0.6 ± 1.36-0.1 ± NA2.0 ± 1.553.4 ± 0.88
Change at week 240.0 ± 1.64-0.9 ± 1.840.0 ± NA2.0 ± 1.702.4 ± 1.97
Change at week 36-0.3 ± 1.49-1.2 ± 2.461.0 ± NA2.3 ± 1.352.1 ± 2.69
Change at week 48-0.8 ± 2.65-1.4 ± 1.97-3.2 ± NA1.1 ± 1.101.6 ± 1.87
Change at week 60-1.7 ± 1.67-2.5 ± 1.93—0.4 ± NA0.3 ± 0.71
SecondaryChange From Baseline in Reticulocytes at Weeks 12, 24, 36, 48, and 60

Change from baseline in reticulocytes at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

Time frame:
Baseline, Weeks 12, 24, 36, 48, and 60
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Reticulocytes at Weeks 12, 24, 36, 48, and 60
10^9 cells/LParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change at week 1216.4 ± 106.94-1.2 ± 95.3468.4 ± NA10.5 ± 90.08-24.7 ± 149.35
Change at week 24-22.5 ± 132.6726.7 ± 102.47-11.3 ± NA-77.1 ± 75.00-52.9 ± 52.41
Change at week 3639.6 ± 99.2282.9 ± 115.86-64.0 ± NA93.0 ± 161.1325.7 ± 96.34
Change at week 488.2 ± 105.7534.4 ± 71.33326.0 ± NA8.9 ± 138.88-45.4 ± 87.01
Change at week 60-9.8 ± 136.44-8.1 ± 109.27—-41.4 ± NA-21.4 ± 175.33
SecondaryChange From Baseline in Lactate Dehydrogenase (LDH) at Weeks 12, 24, 36, 48, and 60

Change from baseline in LDH at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

Time frame:
Baseline, Weeks 12, 24, 36, 48, and 60
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 12, 24, 36, 48, and 60
International units per liter (IU/L)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change at week 12-40.1 ± 176.92-20.0 ± 104.40171.0 ± NA168.8 ± 703.08107.8 ± 471.09
Change at week 2435.7 ± 103.089.9 ± 133.7171.0 ± NA-96.8 ± 144.55-78.5 ± 177.58
Change at week 3654.1 ± 80.9022.6 ± 127.7330.0 ± NA-40.0 ± 177.92-67.7 ± 148.38
Change at week 48172.4 ± 358.0578.0 ± 199.23525.0 ± NA-94.8 ± 124.77-18.4 ± 99.78
Change at week 60207.2 ± 298.8570.4 ± 164.24—-41.0 ± NA43.0 ± 72.12
SecondaryChange From Baseline in Unconjugated Bilirubin at Weeks 12, 24, 36, 48, and 60

Change from baseline in unconjugated bilirubin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.

Time frame:
Baseline, Weeks 12, 24, 36, 48, and 60
Reported as:
Mean · Micromoles per liter (mcmol/L)
Change From Baseline in Unconjugated Bilirubin at Weeks 12, 24, 36, 48, and 60
Micromoles per liter (mcmol/L)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
Change at week 120.6 ± 6.880.3 ± 9.52—-21.9 ± 16.21-3.8 ± 37.57
Change at week 24-2.8 ± 4.55-4.9 ± 13.66—-19.3 ± 20.20-3.4 ± 12.10
Change at week 36-2.8 ± 19.471.6 ± 10.35—-14.9 ± 32.982.1 ± 23.87
Change at week 487.1 ± 31.008.5 ± 11.12—-19.5 ± NA-12.2 ± 21.88
Change at week 600.5 ± 8.638.2 ± 21.07—-0.5 ± NA-13.0 ± NA

Adverse events

Collected over From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Without Delayed Start: Osivelotor 100 mg0/18 (0%)5/18 (27.8%)14/18 (77.8%)
Participants Without Delayed Start: Osivelotor 150 mg0/17 (0%)4/17 (23.5%)13/17 (76.5%)
Participants Without Delayed Start: Osivelotor 200 mg0/1 (0%)1/1 (100%)1/1 (100%)
Participants With Delayed Start: Osivelotor 100 mg1/5 (20%)2/5 (40%)5/5 (100%)
Participants With Delayed Start: Osivelotor 150 mg0/6 (0%)2/6 (33.3%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
PneumoniaInfections and infestations0/181/171/10/50/6
AnaemiaBlood and lymphatic system disorders1/181/170/11/51/6
HaemolysisBlood and lymphatic system disorders1/180/170/11/50/6
SepsisInfections and infestations0/180/170/11/51/6
Thermal burnInjury, poisoning and procedural complications0/180/170/10/51/6
CholecystitisHepatobiliary disorders0/181/170/10/50/6
Vestibular neuronitisInfections and infestations0/181/170/10/50/6
OsteonecrosisMusculoskeletal and connective tissue disorders0/181/170/10/50/6
Tachycardia paroxysmalCardiac disorders1/180/170/10/50/6
GastroenteritisInfections and infestations1/180/170/10/50/6
Most frequent other events
Showing 10 of 86
Most frequent other events
EventParticipants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mg
AnaemiaBlood and lymphatic system disorders0/180/171/10/50/6
Chest painGeneral disorders0/180/171/10/50/6
PyrexiaGeneral disorders0/180/171/10/50/6
ArthralgiaMusculoskeletal and connective tissue disorders1/180/171/11/50/6
Back painMusculoskeletal and connective tissue disorders0/181/171/10/50/6
CoughRespiratory, thoracic and mediastinal disorders0/180/171/10/50/6
MalariaInfections and infestations4/187/170/13/53/6
Urinary tract infectionInfections and infestations2/185/170/13/53/6
PainGeneral disorders2/183/170/10/53/6
MicroalbuminuriaRenal and urinary disorders0/180/170/12/50/6

Baseline characteristics

Safety analysis set included all enrolled participants who had received at least one dose of study drug in this open-label extension (OLE) study. Participants were analyzed according to the assigned daily maintenance dose on study day 1 in the OLE study.

Age, Continuous
Age, Continuous(Years)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mgTotal
Mean33.4 ± 13.7527.2 ± 10.1927.0 ± NA26.4 ± 11.7027.8 ± 14.4129.6 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mgTotal
Female91113428
Male9602219
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mgTotal
Hispanic or Latino000000
Not Hispanic or Latino181715647
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Without Delayed Start: Osivelotor 100 mgParticipants Without Delayed Start: Osivelotor 150 mgParticipants Without Delayed Start: Osivelotor 200 mgParticipants With Delayed Start: Osivelotor 100 mgParticipants With Delayed Start: Osivelotor 150 mgTotal
Race — African101205633
Race — Black or African American8510014
08

Study locations

9 sites
  • Our Lady of the Lake Hospital, Inc.
    Baton Rouge, Louisiana 70808, United States
  • University Medical Center Inpatient Pharmacy
    New Orleans, Louisiana 70112, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • University College Hospital Ibadan
    Ibadan, Oyo/ibadan North 200212, Nigeria
  • Aminu kano Teaching Hospital
    Kano, 700233, Nigeria
  • Lagos University Teaching Hospital
    Lagos, 100254, Nigeria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2025, 25 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2022
First posted
Nov 30, 2022
StartActual
Jan 5, 2023
Primary completionActual
Feb 13, 2025
CompletionActual
Feb 13, 2025
Results first posted
Mar 19, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05632354
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Jan 5, 2023
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Results posted
Mar 19, 2026
Last update
Mar 19, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osivelotor

Start the discussion